Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Asset Writedowns and Impairment (2020 - 2025)

Celularity (CELU) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with -$98000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 16.67% to -$98000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $84000.0, a 100.08% increase, with the full-year FY2024 number at $457000.0, down 62.94% from a year prior.
  • Asset Writedowns and Impairment was -$98000.0 for Q3 2025 at Celularity, down from $8000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $107.2 million in Q2 2023 to a low of -$106.6 million in Q4 2023.
  • A 5-year average of $206333.3 and a median of $139500.0 in 2021 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 49000.0% in 2022, then crashed 11993.64% in 2023.
  • Celularity's Asset Writedowns and Impairment stood at $185000.0 in 2021, then skyrocketed by 384.32% to $896000.0 in 2022, then plummeted by 11993.64% to -$106.6 million in 2023, then surged by 100.22% to $235000.0 in 2024, then plummeted by 141.7% to -$98000.0 in 2025.
  • Per Business Quant, the three most recent readings for CELU's Asset Writedowns and Impairment are -$98000.0 (Q3 2025), $8000.0 (Q2 2025), and -$61000.0 (Q1 2025).